{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-338019","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2026-08-06T20:11:40+00:00","discovered_at":"2026-08-06T20:13:00.710960+00:00","generated_at":"2026-08-06T20:15:51.647762+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xenon Q2 net loss $110.7M; NDA for azetukalner on track for Q3 2026","bullets":["Net loss of $110.7M in Q2 2026 vs $84.7M in Q2 2025; R&D expenses rose to $99.2M.","Cash and securities $1.245B as of June 30, 2026; cash runway into 2029.","NDA submission for azetukalner in FOS remains on track for Q3 2026 after pre-NDA meeting with FDA.","Phase 3 X-NOVA2 topline data in MDD expected H1 2027; X-TOLE3 and X-ACKT enrollment ongoing.","Phase 1 studies for XEN1701, XEN1720 (NaV1.7) and XEN1120 (KV7) expected to complete H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-338019","json":"https://secwatch.observer/filing/0001193125-26-338019.json","markdown":"https://secwatch.observer/filing/0001193125-26-338019.md","text":"https://secwatch.observer/filing/0001193125-26-338019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526338019/0001193125-26-338019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526338019/xene-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:15:51.647762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}